New hope for elderly blood cancer patients with aggressive stem cell transplant approach
NCT ID NCT07500753
Summary
This study is testing a new combination of drugs given before a stem cell transplant to elderly patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has returned or not responded to prior treatment. The goal is to see if this new pre-transplant regimen helps patients live longer without their cancer coming back and is better tolerated. Researchers will enroll about 30 patients aged 50 and older who have a suitable donor for the transplant.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Soochow University
RECRUITINGSuzhou, Jiangsu, 215006, China
Conditions
Explore the condition pages connected to this study.